Indian drug maker Shasun Chemicals & Drugs has agreed to buy the customs synthesis business of French company Rhodia Pharma Solutions, in a move to strengthen its global presence in active pharmaceutical ingredient (API), custom synthesis and contract manufacturing.
As more pharma companies are recognising the benefits of outsourcing, high-potency APIs has become an attractive niche sector for custom pharmaceutical manufacturers, generating double-digit sales growth.
>Shasun, already a leading API producer in India, has existing contract manufacturing agreements with other major Indian companies such as Ranbaxy Laboratories and Glenmark.
Last year Shasun also managed to forge large contract manufacturing deals with multinational companies such as Alpharma and Codexis in the US.
However, the company has been actively looking to make overseas acquisitions that will stretch its contract research and manufacturing capabilities further across the globe.
The acquisition agreement with Rhodia, to be completed by March 31, includes all of Rhodia Pharma's development and custom manufacturing services in the US, Europe and Asia, as well as two UK manufacturing sites manufacturing sites located at Dudley and Annan.
"Shasun will be in a better situation to serve pharmaceutical industry clients throughout the drug life cycle by offering services for pre-launch, launch, and post launch supply as well as late life cycle and also expand its customer base across innovator and emerging pharma companies," said N Govindarajan, CEO.